Abstract
The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.
| Original language | English |
|---|---|
| Pages (from-to) | 715-718 |
| Number of pages | 4 |
| Journal | Drugs under Experimental and Clinical Research |
| Volume | 14 |
| Issue number | 11 |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology (medical)
- Drug Discovery
- Pharmacology
Cite this
Pathological brain ageing : Evaluation of the efficacy of a pharmacological aid. / Guarnaschelli, C.; Fugazza, G.; Pistarini, C.
In: Drugs under Experimental and Clinical Research, Vol. 14, No. 11, 1988, p. 715-718.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pathological brain ageing
T2 - Evaluation of the efficacy of a pharmacological aid
AU - Guarnaschelli, C.
AU - Fugazza, G.
AU - Pistarini, C.
PY - 1988
Y1 - 1988
N2 - The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.
AB - The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.
UR - http://www.scopus.com/inward/record.url?scp=0024215918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024215918&partnerID=8YFLogxK
M3 - Article
C2 - 3246216
AN - SCOPUS:0024215918
VL - 14
SP - 715
EP - 718
JO - Drugs under Experimental and Clinical Research
JF - Drugs under Experimental and Clinical Research
SN - 0378-6501
IS - 11
ER -